Press Releases

As part of our ongoing commitment to environmental stewardship and industry leadership in sustainable clinical research, LabConnect is proud to announce our partnership with Kits4Life, an initiative of the MedSurplus Alliance. This collaboration reflects our broader ESG strategy and strengthens LabConnect's role as the world's most agile and responsible central laboratory services provider. Through this partnership, LabConnect will work with sponsors and clinical sites to identify and

ViruSure, a global leader in pathogen safety testing for biopharmaceuticals, and Oxford Nanopore Technologies (“Oxford Nanopore”) (LSE: ONT), the company behind a new generation of molecular sensing technology based on nanopores, today announce the launch of the industry’s first Good Laboratory Practice (GLP) validated adventitious viral agent (AVA) detection test using nanopore-based sequencing technology. The ViruSure test has been developed and evaluated under r

AbOliGo, a biotechnology company pioneering high- performance antibody-oligonucleotide conjugates (AOCs), today announced the successful close of an oversubscribed seed funding round. The raise attracted strong support from leading early-stage life sciences investors and will enable AbOliGo to scale manufacturing, expand its team, and drive commercial growth. Multiomic applications such as spatial biology, proteomics, and single-cell analysis which incorporate AOCs, continue to be w

Fapon Biopharma, a biotech in developing therapeutic antibodies and fusion proteins, is delighted to announce the completion of the first patient enrollment  in China for its Phase I clinical trial of FP008 , a first-in-class immunotherapy for solid tumors, at Zhejiang Cancer Hospital. The patient has completed the Dose Limiting Toxicity (DLT) observation period with a favorable safety profile. The trial aims to evaluate the safety and tolerability of FP008 in patients with advanced soli

Kashiv BioSciences, LLC and MS Pharma today announced that the companies have entered into a license and supply agreement for ADL-018, Kashiv BioSciences’ biosimilar candidate to XOLAIR® (bOmalizumab) in the Middle East and North Africa (MENA) region. IQVIA reported global sales of ~$4.5 billion and ~$60 million in MENA in 2024. Under the terms of the agreement, Kashiv BioSciences is responsible for the development of the product within the agreed territories. MS Pharma wi

Anbogen Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for ABT-301, enabling the initiation of a Phase 1/2 clinical trial in combination with tislelizumab and bevacizumab for patients with metastatic colorectal cancer (mCRC). This open-label, multi-center international study plans to enroll 66 patients with proficient mismatch repair (pMMR) or non-microsatellite instability-high (non-MSI-H) mC

Alveolus Bio, a pioneering respiratory drug development biotech company founded by Dr. Vivek Lal from University of Alabama at Birmingham, AL, has announced a strategic financing round led by Shilpa Medicare Limited (BSE: 524742) (NSE: SHILPAMED), a prominent global pharmaceutical company with extensive expertise in respiratory therapeutics manufacturing and biotechnology innovation. Through this collaboration, Shilpa Biologics, the biologics arm of Shilpa Medicare, will become Alve

Ahead of the publication of its business results for the second quarter of 2025 on Wednesday, August 6, Bayer AG is providing an update on key financial figures. Due to a better-than-expected business performance at Pharmaceuticals in the first half of the year, Bayer is raising its full-year guidance for currency-adjusted sales and earnings. On a currency-adjusted basis (i.e. based on the average monthly exchange rates in 2024), Bayer now expects to post Group sales of 46 to 48 billion euros

GRI Bio, Inc. a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today reported interim 6-week biomarker results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”). In the second interim analysis, biomarkers of fibrogenesis and fibrolysis, or the formation and degradation of col

The Pharmaceutical Launch Excellence Summit (PHLEX Summit), the only dedicated event for pharmaceutical launch strategy and execution, is set to return for its second annual edition on 2–3 December 2025 at the Hilton London Olympia.